Traders should monitor for FDA feedback ahead of the December 2026 PDUFA date; any safety concerns or delays could trigger volatility. Positive momentum supports long positioning ahead of decision, but risks remain around approval and commercial uptake.
Price Chart
Executive Summary
The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatment for adult hypertension, and set a PDUFA action date of December 22, 2026. While the Phase 2 Explore-OSA trial missed its primary endpoint of reducing apnea-hypopnea index in sleep apnea patients, it showed clinically meaningful blood pressure reduction and a favorable safety profile, supporting the drug's potential in resistant hypertension.
Key Facts
- FDA accepted NDA for lorundrostat with PDUFA date of December 22, 2026
- Lorundrostat demonstrated 6.2 mmHg placebo-adjusted systolic BP reduction in Explore-OSA trial (p < 0.0003)
- Primary endpoint (AHI reduction) in Explore-OSA trial was not met
- Drug showed favorable safety profile with no serum potassium excursions above 5.5 mmol/L
- NDA supported by positive Phase 3 Launch-HTN and Phase 2 Advance-HTN trials
Financial Impact
Potential blockbuster approval in 2026 for a $219B U.S. hypertension market with high unmet need
Risk Factors
- FDA may require additional data or delay approval despite acceptance
- Failure in Explore-OSA primary endpoint may raise questions about broader indications
- Commercial success depends on differentiation from existing antihypertensives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $23.56 (−9.70%) |
Jul 23, 2026 10w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $23.56 (−11.79%) |
Jul 21, 2026 10w ago | Insider Cluster | $27.52 $26.61 | ▼ −3.31% | ▼ −5.87% | $23.56 (−14.39%) |
Jul 16, 2026 11w ago | Insider Cluster | $27.08 $26.09 | ▼ −3.66% | ▼ −7.27% | $23.56 (−13.00%) |
Jun 30, 2026 13w ago | 144 | $26.89 $26.35 | ▼ −2.01% | ▲ +0.18% | $23.56 (−12.38%) |
Jun 29, 2026 13w ago | 144 | $26.88 $26.71 | ▼ −0.63% | ▼ −0.35% | $23.56 (−12.35%) |
Jun 18, 2026 15w ago | Insider Cluster | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 17, 2026 15w ago | 144 | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.94 $28.96 | ▲ +20.97% | ▲ +19.08% | $23.56 (−1.59%) |
Jun 3, 2026 17w ago | 8-K | $25.06 $27.69 | ▲ +10.49% | ▲ +11.49% | $23.56 (−5.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access